• If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent numbers give you plenty to think about.
• The stock last closed at US$40.29, with a 2.9% return over 7 days and 14.2% over 30 days, set against a year to date return of a 23.1% decline and a 37.4% decline over 1 year.
• Those returns sit alongside a longer term picture, with a 49.2% decline over 3 years but a 17.3% gain over 5 years. This mixed performance means recent moves can look very different depending on how far back you zoom.
• Novo Nordisk currently has a valuation score of 5 out of 6, and the sections that follow will compare what different valuation methods say about the stock while pointing to a more complete way to think about value at the end of the article.

Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a company may generate in the future and discounts those amounts back to what they could be worth today.

For Novo Nordisk, the latest twelve month free cash flow is DKK 52,097.16m, or DKK 52.10b. Analysts have provided detailed forecasts for the next few years, and Simply Wall St extends those projections out to 2035. Within that path, free cash flow for 2030 is projected at DKK 107,429.50m, or about DKK 107.43b. Each future year is discounted back to today using a 2 Stage Free Cash Flow to Equity model.

Adding all of those discounted cash flows produces an estimated intrinsic value of US$111.54 per share. Compared with the recent share price of US$40.29, the DCF output implies the stock is 63.9% undervalued based on these specific assumptions and projections.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 63.9%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Novo Nordisk Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it links what you pay for the stock directly to the earnings the business is already generating. The level of P/E investors are comfortable with usually reflects what they expect for future earnings growth, as well as how risky they see those earnings to be.

Novo Nordisk currently trades on a P/E of 11.06x. That sits below the wider Pharmaceuticals industry average P/E of 15.84x and also below the peer group average of 19.24x. On the surface, that points to a lower price tag per dollar of earnings compared with many other drug makers.

Simply Wall St also calculates a proprietary “Fair Ratio” for Novo Nordisk of 25.14x. This Fair Ratio is designed to reflect the P/E that might be expected given factors such as the company’s earnings growth profile, its industry, profit margins, market capitalization and specific risks. Because it pulls these elements together into a single figure, it can give a more tailored reference point than a simple comparison with peers or an industry average, which may not share the same growth or risk characteristics. With Novo Nordisk’s current P/E of 11.06x sitting well below the Fair Ratio of 25.14x, the shares appear undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Novo Nordisk Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and this is where Narratives come in. They allow you to set out your own story for Novo Nordisk, link that story to clear forecasts for revenue, earnings and margins, and then see a fair value that you can easily compare with the current share price on Simply Wall St’s Community page. Narratives are updated when new information such as earnings or news is added. One investor might build a Narrative that leads to a fair value of about US$65.50 per ADR, while another, using different assumptions, might reach about US$95 per ADR. This shows how the same stock can look very different depending on the story and numbers you choose.

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.